Prologue Mathematics Physics Chemistry Biology Medicine  
ECHO & Imaging CAD Valvular disease Arytmology Cardiomyopathy & HF Angiology Other    
     
2015 Pericarditis

2014 Hypertrophic cardiomyopathy

2013 Myocarditis (position statement)

2012 Acute and choronic heart failure

2010 Device therapy in heart failure

2007 Endomyocardial biopsy






český souhrn

český souhrn

český souhrn

excel

excel

excel

excel

excel
           
Hypereosinophilic syndrom / Loeffler Endocarditis

2015 Medscape: Loeffler Endocarditis: Background, Pathophysiology, Frequency

2013 Roufose F.: How they contribute to endothelial damage and dysfunction, 16 th international vasculitis & ANCA workshop.

2013 Podjasek J.C., Butterfield J.H.: Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature, Leukemia Research 37 (2013) 392– 395.

2012 Valent P. & al.:
ICON: Eosinophil Disorders, Consensus document of World Allergy Organization, WAO Journal, December 2012.

2012 Arefi M. & al
.: Response to imatinib mesylate in patients with hypereosinophilic syndrome, Int J Hematol (2012) 96:320–326

2011 Yanagisawa T. & al.
: Clinical Significance of Corticosteroid Therapy for Eosinophilic Myocarditis K. Heart Jurnal, March 2011, Vol 52, No2.

2011 Faria R & al..: Loeffler’s endocarditis - A case report, Rev Port Cardiol. 2012; 31(6): 445-448.

2010 Hilty C. K. & al
.:Cardiac MRI finding of Loeffler Enodcarditis: A Case Report with Clinical and Pathologic Correlation, The Open Cardiovascular Imaging Journal, 2010, 2, 10-13.

2009 Taner S. & al.: Cardiac Involvement in hypereosinophylic syndrom, Images in Cardiovascular Medicine, Volume 36, Number 6, 2009.


  Immunoadsorption

2015 Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy

2013 Schwartz, J.& al. : Guidelines on the Use of Therapeutic Apheresis in Clinical practice, Journal of Clinical Apheresis 28:145–284 (2013)

2012 Michael Arad M, Freimark D
.: Predicting Prognosis in Dilated Cardiomyopathy, IMAJ, VOL 14 , November 2012

2012 Hazebroek M. & Dennert R. & Heymans S. : Idiopathic dilated cardiomyopathy: possible triggers and treatment strategie, Neth Heart J (2012) 20:332–335.

2010 Dösch A., Katus H. A.
: Erfahrungen mit therapeutischer Immunadsorption bei Dilatativer Kardiomyopathie, Eine mögliche Alternative zur Herztransplantation, Transplantationsmedizin, 2010, 22. Jahrg., S. 363.

2009 Herda R.L, Felix, B, S.,Staudt A.:
Immunoadsorption in patients with dilated cardiomyopathy, Atherosclerosis Supplements 10 (2009) 126–128.

2008 Ikeda U. & al.
: Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy
and Heart Failure, Current Cardiology Reviews, 2008, 4, 219-222 219

2006 Felix, B, S, Staudt A.: Non-specific immunoadsorption in patients with dilated cardiomyopathy: Mechanisms and clinical effects, International Journal of Cardiology 112 (2006) 30–33

2004 Staudt & al.: Potential Role of Humoral Immunity in Cardiac Dysfunction of Patients Suffering From Dilated Cardiomyopathy,Journal of the American College of Cardiology Vol. 44, No. 4, 2004

2002 Staudt A.: Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy

 
     
Treatment myocarditis / EMB
1995 Mason

2001 Wojnicz

2003 Kühl Interferon beta

2008 Kindermann predictors of outcome

2009 Friedrich MR

2009 Timic

2010 Dennert PVB19

2010 Korkusuz MR

2011 Consensus statement, CV Pathology

2011 Viral serology

2012 Kinderman MR Upadate

2013 Friedrich MR

2014 Luetkens MR


  Questions from the live webinar - 15 Sept 2015

Dennert at al. Antivir Ther. 2010;15(2):193-201